Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25588073 | 0.80 | IDO1 (0.50) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| SCHEMBL1757600 | 0.78 | IDO1 (0.53) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| SCHEMBL28309519 | 0.78 | IDO1 (0.48) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| SCHEMBL2095744 | 0.78 | SLC6A4 (0.49) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| SCHEMBL15821526 | 0.78 | KDM4E (0.52) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| SCHEMBL19157551 | 0.78 | IDO1 (0.48) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| SCHEMBL24186105 | 0.78 | IDO1 (0.44) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| Hydrochloric Acid SCHEMBL15065821 | 0.77 | IDO1 (0.55) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| Hydrochloric Acid SCHEMBL21332846 | 0.77 | IDO1 (0.55) | KDM4ESMN1; SMN2IDO1AGXTGAA | |
| Hydrochloric Acid SCHEMBL29289846 | 0.77 | IDO1 (0.50) | KDM4ESMN1; SMN2IDO1AGXTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | KDM4E 4269/4885SMN1; SMN2 2135/4885IDO1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.